Physician profile
Kimber Knapp
NPI 1801668017
$5,815.98
in general payments reported to CMS, 2019-2025
44 companies · $4,213 in 2025
The $4,213 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $19.38 · 2024: $1,584 · 2025: $4,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,440 · Education: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,440.04 |
| Education | $375.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $682.52 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Astrazeneca Pharmaceuticals LP | $617.56 | 2024-2025 | Imfinzi, Calquence, Enhertu |
| Merck Sharp & Dohme LLC | $412.18 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Sobi, INC | $345.04 | 2024-2025 | |
| Janssen Biotech, INC. | $315.45 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $288.77 | 2024-2025 | |
| Caris Mpi, INC. | $278.63 | 2025 | Mi Cancer Seek |
| Astellas Pharma US INC | $251.74 | 2024-2025 | Xtandi, Vyloy |
| Fennec Pharmaceuticals, INC. | $206.60 | 2025 | Fyarro |
| Karyopharm Therapeutics INC. | $201.04 | 2025 | Xpovio |
| Incyte Corporation | $191.94 | 2025 | Monjuvi, Zynyz, Jakafi |
| Exelixis INC. | $174.96 | 2025 | Cabometyx |
| Lilly USA, LLC | $171.88 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $142.94 | 2024-2025 | |
| Dendreon Pharmaceuticals LLC | $136.02 | 2024-2025 | Provenge |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimber Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.